INTRODUCTION

51
Candida species are the most commonly encountered fungal pathogens in the hospital effectiveness against some of these emerging non-albicans species with resistance 59 rates up to 5% (31).
60
A major medical advance in fungal therapeutics was the development of the 61 echinocandin drug class, which targets cell wall glucan synthesis, a major cell wall 62 structural component in Candida species (12, 14, 15, 34 
RESULTS
168
In vitro susceptibility testing and in vivo organism fitness. glabrata, and C. parapsilosis, respectively (see Table 2 ). The AUC/MIC (both total and 208 free drug) values associated with the stasis and 1-log kill endpoints are also shown in 209 
DISCUSSION
219
The synthesis of glucans in Candida has proven to be an effective drug target infections. This is particularly relevant given the emergence of echinocandin resistance 255 and echinocandin/azole co-resistance in C. glabrata (1, 29, 33) .
256
The ability of pre-clinical PD studies to predict efficacy of antimicrobial agents in Acknowledgments: These studies were funded by a research grant from Merck. 
